Top 10 Stocks to Buy According to Ariel Investments
In this article, we will highlight the Top 10 Stocks to Buy According to Ariel Investments. Long-term bond yields have risen significantly to the highest level since 2007.
Charles River Laboratories International Inc. (CRL)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Harris Associates Natixis Global Asset Management | 2,241,144 | $508,269,048 | +5% | 0.67% |
| 2. | Ariel Investments John W. Rogers | 1,506,185 | $341,587,697 | +5% | 3.41% |
| 3. | Citadel Investment Group Ken Griffin | 1,193,601 | $270,696,771 | -2% | 0.03% |
| 4. | Millennium Management Israel Englander | 486,462 | $110,324,717 | -48% | 0.04% |
| 5. | Gotham Asset Management Joel Greenblatt | 433,146 | $98,233,181 | +21% | 0.23% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $174.54 | 25 | $4,363.50 | 27,448 | 2026-03-03 | Filing | |
| $165.01 | 6,075 | $1,002,435.75 | 183,639 | 2025-02-20 | Filing | |
| $164.63 | 1,514 | $249,249.82 | 55,058 | 2025-02-20 | Filing | |
| $187.82 | 1,322 | $248,298.04 | 44,449 | 2023-11-20 | Filing | |
| $178.05 | 5,620 | $1,000,641.00 | 202,643 | 2023-11-14 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $300.00 | 33,561 | $10,068,300.00 | 31,596 | 2026-08-25 | Filing | |
| $294.12 | 2,039 | $599,710.68 | 4,807 | 2026-08-19 | Filing | |
| $285.24 | 573 | $163,442.52 | 1,438 | 2026-08-18 | Filing | |
| $279.90 | 6,500 | $1,819,350.00 | 36,013 | 2026-08-11 | Filing | |
| $279.66 | 3,714 | $1,038,657.24 | 4,807 | 2026-08-11 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 4,239,752 | $961,533,236 | 0.04% | |
| 2. | 3,798,560 | $861,475,349 | 0.01% | |
| 3. | 3,149,288 | $714,227,026 | 0.02% | |
| 4. | 2,984,785 | $676,919,391 | 0.05% | |
| 5. | 2,210,979 | $501,427,927 | 0.02% |
News See All
Is Charles River Laboratories International, Inc. (CRL) A Good Stock To Buy Now?
Is CRL a good stock to buy? We came across a bullish thesis on Charles River Laboratories International, Inc. on TradersPro’s Substack. In this article, we will summarize the bulls’ thesis on CRL.
Charles River Labs (CRL) Pulled Back Due to AI Disruption Fears
Madison Small Cap Fund, managed by Madison Funds, released its Q1 2026 investor letter. A copy of the letter is available to download here.
Charles River Laboratories International, Inc. (NYSE:CRL) Q1 2026 Earnings Call Transcript
Charles River Laboratories International, Inc. (NYSE:CRL) Q1 2026 Earnings Call Transcript May 7, 2026Charles River Laboratories International, Inc. beats earnings expectations.
Charles River Laboratories International (CRL) Positioned to Benefit from Preclinical Research Activity and Biotech Funding Recovery
ClearBridge Investments, a global equity manager, recently published first-quarter 2026 commentary for its “Small Cap Growth Strategy”. A copy of the letter can be downloaded here.
Charles River Laboratories International (CRL) Gains on Strong Results and Resilient Drug Outsourcing Demand
Ariel Investments, an investment management company, released its "Ariel Appreciation Fund" fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here.
Charles River Laboratories International (CRL) Faces Biotech R&D Spending Headwinds
Invesco Ltd‘s “Small Cap Value Fund” released its Q4 2025 investor letter. A copy of the letter can be downloaded here.
Baird Maintains Outperform Rating on Charles River Laboratories International, Inc. (CRL)
Charles River Laboratories International, Inc. (NYSE:CRL) is one of the 10 best life sciences stocks to buy according to hedge funds.
10 Best Life Sciences Stocks to Buy According to Hedge Funds
Following a difficult start in 2025, the ever-evolving life sciences segment recovered strongly in the latter half of the year.
Charles River Laboratories International, Inc. (NYSE:CRL) Q4 2025 Earnings Call Transcript
Charles River Laboratories International, Inc. (NYSE:CRL) Q4 2025 Earnings Call Transcript February 18, 2026Charles River Laboratories International, Inc. misses on earnings expectations.
Hedge Fund Resource Center